Protalix Biotherapeutics (PLX) Up On Takeover Speculation
Up)
According to reports from Globes Online, the Protalix Biotherapeutics (AMEX: PLX) CEO commented on recent rumors that Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) would acquire the company, saying that they would not sell unless they receive an exceptional offer that it cannot refuse. The CEO said there are no such offers on the table at this time.
CEO David Aviezer said while a sale may not happen, they company is seeking a strategic partner to market its Gaucher's drug and Teva is a reasonable candidate.
Teva has no investment in Protalix but relations are very good because they share the same chairman - Eli Hurvitz - and have two joint projects.
Shares of PLX are up 12% today $9.48.
Link to Globes Online Article
CEO David Aviezer said while a sale may not happen, they company is seeking a strategic partner to market its Gaucher's drug and Teva is a reasonable candidate.
Teva has no investment in Protalix but relations are very good because they share the same chairman - Eli Hurvitz - and have two joint projects.
Shares of PLX are up 12% today $9.48.
Link to Globes Online Article
You May Also Be Interested In
- Teva Provides Updated 2012 Non-GAAP Financial Outlook; Updated 2012 Non-GAAP Diluted EPS of $5.30 to $5.40
- Patriot Coal (PCX) Hammered on Bankruptcy Worries
- Rhoen-Klinkum to recommend Fresenius (FMS) takeover offer -Bloomberg
Create E-mail Alert Related Categories
RumorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
